FARMERS & MERCHANTS TRUST Co OF LONG BEACH Has $1.40 Million Stake in AbbVie Inc. $ABBV

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 64.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,027 shares of the company’s stock after selling 11,075 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in AbbVie were worth $1,395,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the second quarter worth approximately $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the 2nd quarter worth $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth $39,000. 70.23% of the stock is owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year drug‑pricing agreement with the White House that grants exemptions from certain tariffs and future pricing mandates in exchange for lower Medicaid pricing and a pledge to invest $100 billion in U.S. R&D and capital over the next decade — market sees tariff relief and large domestic investment as net positives for cash flow visibility and political risk reduction. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to an exclusive global licensing/partnering deal for RC148 (a PD‑1/VEGF bispecific) with RemeGen — up to ~$5.6B — boosting its oncology pipeline and giving upside to future sales if the asset progresses. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: Operational and manufacturing expansion: AbbVie is acquiring an Arizona drug‑delivery/manufacturing facility and the SmartDose on‑body system rights from West Pharma, and announced a $175M investment in an Arizona drug‑device plant — these moves support supply security, onshoring and next‑gen product delivery capacity. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Regulatory engagement: AbbVie (with peers) is leading calls for the FDA to update post‑approval change rules — potential long‑run operational implications, but not an immediate earnings driver. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: Clinical pipeline progress: Phase‑2 readout/trial completion for ABBV‑932 (bipolar depression) was reported — positive for pipeline optionality but early stage and uncertain commercial timing. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion
• Neutral Sentiment: Analyst / retail attention: Several bullish analyst pieces and increased investor searches highlight AbbVie’s dividend and value characteristics — supportive sentiment but not a direct fundamental change. Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
• Negative Sentiment: Revenue and margin risk from price concessions: the White House pact requires lower Medicaid pricing and expanded affordable patient offerings, which could blunt near‑term revenue/margin growth for products used widely in public programs — investors will watch guidance and product‑level impact. Abbvie, US reach agreement to cut drug prices

AbbVie Trading Up 0.2%

Shares of AbbVie stock opened at $220.51 on Wednesday. The firm’s 50 day moving average is $226.84 and its 200 day moving average is $216.04. The firm has a market capitalization of $389.72 billion, a PE ratio of 167.05, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ABBV shares. Evercore ISI upped their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Bank of America lifted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $246.89.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.